137 related articles for article (PubMed ID: 16512320)
1. The long-term health and economic benefits of DOTS implementation in Ecuador.
Oxlade O; Vaca J; Romero E; Schwartzman K; Graham B; Hernandez L; Tannenbaum T; Menzies D
Can J Public Health; 2006; 97(1):14-9. PubMed ID: 16512320
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.
Tseng CL; Oxlade O; Menzies D; Aspler A; Schwartzman K
BMC Public Health; 2011 Jan; 11():55. PubMed ID: 21269503
[TBL] [Abstract][Full Text] [Related]
3. Domestic returns from investment in the control of tuberculosis in other countries.
Schwartzman K; Oxlade O; Barr RG; Grimard F; Acosta I; Baez J; Ferreira E; Melgen RE; Morose W; Salgado AC; Jacquet V; Maloney S; Laserson K; Mendez AP; Menzies D
N Engl J Med; 2005 Sep; 353(10):1008-20. PubMed ID: 16148286
[TBL] [Abstract][Full Text] [Related]
4. Impact of DOTS expansion on tuberculosis related outcomes and costs in Haiti.
Jacquet V; Morose W; Schwartzman K; Oxlade O; Barr G; Grimard F; Menzies D
BMC Public Health; 2006 Aug; 6():209. PubMed ID: 16911786
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness.
Pantoja A; Lönnroth K; Lal SS; Chauhan LS; Uplekar M; Padma MR; Unnikrishnan KP; Rajesh J; Kumar P; Sahu S; Wares F; Floyd K
Int J Tuberc Lung Dis; 2009 Jun; 13(6):705-12. PubMed ID: 19460245
[TBL] [Abstract][Full Text] [Related]
6. [Tuberculosis in Asia].
Kekkaku; 2002 Oct; 77(10):693-7. PubMed ID: 12440145
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of treating multidrug-resistant tuberculosis.
Resch SC; Salomon JA; Murray M; Weinstein MC
PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
[TBL] [Abstract][Full Text] [Related]
8. DOTS implementation in a middle-income country: development and evaluation of a novel approach.
Vaca J; Peralta H; Gresely L; Cordova R; Kuffo D; Romero E; Tannenbaum TN; Houston S; Graham B; Hernandez L; Menzies D
Int J Tuberc Lung Dis; 2005 May; 9(5):521-7. PubMed ID: 15875923
[TBL] [Abstract][Full Text] [Related]
9. Costs and benefits of improving tuberculosis control: the case of Thailand.
Sawert H; Kongsin S; Payanandana V; Akarasewi P; Nunn PP; Raviglione MC
Soc Sci Med; 1997 Jun; 44(12):1805-16. PubMed ID: 9194242
[TBL] [Abstract][Full Text] [Related]
10. Estimating tuberculosis cases and their economic costs averted in the United States over the past two decades.
Castro KG; Marks SM; Chen MP; Hill AN; Becerra JE; Miramontes R; Winston CA; Navin TR; Pratt RH; Young KH; LoBue PA
Int J Tuberc Lung Dis; 2016 Jul; 20(7):926-33. PubMed ID: 27287646
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two cash transfer strategies to prevent catastrophic costs for poor tuberculosis-affected households in low- and middle-income countries: An economic modelling study.
Rudgard WE; Evans CA; Sweeney S; Wingfield T; Lönnroth K; Barreira D; Boccia D
PLoS Med; 2017 Nov; 14(11):e1002418. PubMed ID: 29112693
[TBL] [Abstract][Full Text] [Related]
12. Non-clinical factors associated with TB: important for DOTS impact evaluation and disease elimination.
Hill PC; Whalen CC
Trans R Soc Trop Med Hyg; 2014 Sep; 108(9):523-5. PubMed ID: 25059524
[TBL] [Abstract][Full Text] [Related]
13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the Health X Project for tuberculosis control in China.
Wang WB; Zhang H; Petzold M; Zhao Q; Xu B; Zhao GM
Int J Tuberc Lung Dis; 2014 Aug; 18(8):939-45. PubMed ID: 25199008
[TBL] [Abstract][Full Text] [Related]
15. The value of tuberculosis elimination and of progress in tuberculosis control in twentieth-century England and Wales.
Hickson KJ
Int J Tuberc Lung Dis; 2009 Sep; 13(9):1061-7. PubMed ID: 19723393
[TBL] [Abstract][Full Text] [Related]
16. Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Directly Observed Treatment.
Khan MA; Walley JD; Witter SN; Imran A; Safdar N
Health Policy Plan; 2002 Jun; 17(2):178-86. PubMed ID: 12000778
[TBL] [Abstract][Full Text] [Related]
17. Drones and digital adherence monitoring for community-based tuberculosis control in remote Madagascar: A cost-effectiveness analysis.
Bahrainwala L; Knoblauch AM; Andriamiadanarivo A; Diab MM; McKinney J; Small PM; Kahn JG; Fair E; Rakotosamimanana N; Grandjean Lapierre S
PLoS One; 2020; 15(7):e0235572. PubMed ID: 32634140
[TBL] [Abstract][Full Text] [Related]
18. Prioritising between direct observation of therapy and case-finding interventions for tuberculosis: use of population impact measures.
Heller RF; Gemmell I; Edwards R; Buchan I; Awasthi S; Volmink JA
BMC Med; 2006 Dec; 4():35. PubMed ID: 17181867
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis care strategies and their economic consequences for patients: the missing link to end tuberculosis.
Getahun B; Wubie M; Dejenu G; Manyazewal T
Infect Dis Poverty; 2016 Nov; 5(1):93. PubMed ID: 27799063
[TBL] [Abstract][Full Text] [Related]
20. Global investments in TB control: economic benefits.
Laxminarayan R; Klein EY; Darley S; Adeyi O
Health Aff (Millwood); 2009; 28(4):w730-42. PubMed ID: 19567413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
